{
    "root": "54623e7c-32c6-407a-b619-a52c14df0fa2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMONDYS 45",
    "value": "20240112",
    "ingredients": [
        {
            "name": "casimersen",
            "code": "X8UHF7SX0R"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "potassium chloride",
            "code": "660YQ98I10"
        },
        {
            "name": "potassium phosphate, monobasic",
            "code": "4J9FJ0HL51"
        },
        {
            "name": "sodium phosphate, dibasic, anhydrous",
            "code": "22ADO53M6F"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.",
    "contraindications": "Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45 ( 2.1 ) 30 milligrams per kilogram of body weight once weekly ( 2.2 ) Administer as an intravenous (IV) infusion over 35 to 60 minutes via an in-line 0.2 micron filter ( 2.2 , 2.4 ) Dilution required prior to administration ( 2.3 )",
    "warningsAndPrecautions": "AMONDYS 45 injection is supplied in single dose vials. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles.\n\n                        â€¢ Single-dose vials containing 100 mg/2 mL (50 mg/mL)  NDC 60923-227-02",
    "adverseReactions": "AMONDYS 45 is contraindicated in patients with known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity, including angioedema and anaphylaxis, have occurred in patients receiving AMONDYS 45 [see Warnings and Precautions (5.1)]."
}